CR10552A - Metodos para tratar y limitar trastornos fibroticos y queloides - Google Patents

Metodos para tratar y limitar trastornos fibroticos y queloides

Info

Publication number
CR10552A
CR10552A CR10552A CR10552A CR10552A CR 10552 A CR10552 A CR 10552A CR 10552 A CR10552 A CR 10552A CR 10552 A CR10552 A CR 10552A CR 10552 A CR10552 A CR 10552A
Authority
CR
Costa Rica
Prior art keywords
treat
disorders
keloid
methods
limit
Prior art date
Application number
CR10552A
Other languages
English (en)
Spanish (es)
Inventor
Luciana Biagini Lopes
Elizabeth J Furnish
Charles Robert Flynn
Padmini Komalavilas
Alyssa Panitch
Colleen M Brophy
Original Assignee
Univ Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arizona filed Critical Univ Arizona
Publication of CR10552A publication Critical patent/CR10552A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CR10552A 2006-07-12 2009-01-09 Metodos para tratar y limitar trastornos fibroticos y queloides CR10552A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83027906P 2006-07-12 2006-07-12
US84904106P 2006-10-02 2006-10-02

Publications (1)

Publication Number Publication Date
CR10552A true CR10552A (es) 2009-05-04

Family

ID=38924094

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10552A CR10552A (es) 2006-07-12 2009-01-09 Metodos para tratar y limitar trastornos fibroticos y queloides

Country Status (13)

Country Link
US (1) US20110028398A1 (enExample)
EP (1) EP2051727A4 (enExample)
JP (1) JP5048772B2 (enExample)
KR (1) KR101267217B1 (enExample)
AU (1) AU2007272578B2 (enExample)
BR (1) BRPI0714383A2 (enExample)
CA (1) CA2657263A1 (enExample)
CR (1) CR10552A (enExample)
DO (1) DOP2009000005A (enExample)
MX (1) MX2009000359A (enExample)
NZ (1) NZ574717A (enExample)
SG (1) SG173369A1 (enExample)
WO (1) WO2008008772A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2617431B1 (en) 2007-01-10 2017-04-12 Purdue Research Foundation Polypeptide inhibitors of HSP27 kinase and uses therefor
JP5703466B2 (ja) 2007-08-07 2015-04-22 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ キナーゼ阻害薬およびその使用
WO2010027831A1 (en) * 2008-08-25 2010-03-11 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to ctgf
BRPI0922448A2 (pt) 2008-12-10 2021-02-17 Purdue Research Foundation inibidor com base em peptídeo penetrante celular de quinases
WO2011017132A2 (en) 2009-07-27 2011-02-10 Purdue Research, Foundation Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
WO2013134177A1 (en) * 2012-03-05 2013-09-12 Capstone Therapeutics Corp. Methods and compositions for improving spinal surgery outcomes
US9452218B2 (en) 2012-03-09 2016-09-27 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
KR102166543B1 (ko) * 2014-06-02 2020-10-16 주식회사 젬백스앤카엘 켈로이드 억제용 조성물 및 그 억제 방법
US20170275650A1 (en) * 2014-07-22 2017-09-28 The Regents Of The University Of California Endosomal escape domains for delivery of macromolecules into cells
KR101667900B1 (ko) * 2016-01-15 2016-10-21 테고사이언스 (주) 켈로이드성 피부 또는 켈로이드 흉터 진단용 바이오마커 단백질 및 이의 이용

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5280038A (en) * 1992-03-13 1994-01-18 Virginia Commonwealth University Histidine as a protective agent in cardiac surgery and myocardial ischemic syndrome
US5985635A (en) * 1996-11-15 1999-11-16 Incyte Pharmaceuticals, Inc. Nucleic acids encoding novel human serine/threonine protein kinases
US7556722B2 (en) * 1996-11-22 2009-07-07 Metzger Hubert F Electroplating apparatus
US6475490B1 (en) * 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
AU2001249214A1 (en) * 2000-03-15 2001-09-24 The Brigham And Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
ES2432225T3 (es) * 2001-08-23 2013-12-02 Arizona Board Of Regents Reactivos y procedimientos para terapias del músculo liso
AU2003260668A1 (en) * 2002-04-01 2003-10-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Biological affinity based delivery systems
ATE332703T1 (de) * 2003-02-21 2006-08-15 Univ Arizona Verwendung von hsp20 zur förderung der wundheilung und / oder zur reduzierung von narbenbildung
CA2542639A1 (en) * 2003-10-17 2005-04-28 Arizona Board Of Regents Novel heat shock protein 20-related polypeptides and uses therefor
JP2009033589A (ja) * 2007-07-30 2009-02-12 Ricoh Co Ltd 画像形成装置、プログラムおよび記録媒体

Also Published As

Publication number Publication date
DOP2009000005A (es) 2009-04-30
SG173369A1 (en) 2011-08-29
EP2051727A4 (en) 2012-03-14
JP5048772B2 (ja) 2012-10-17
EP2051727A2 (en) 2009-04-29
CA2657263A1 (en) 2008-01-17
WO2008008772A2 (en) 2008-01-17
WO2008008772A3 (en) 2008-10-16
US20110028398A1 (en) 2011-02-03
JP2009543800A (ja) 2009-12-10
MX2009000359A (es) 2009-05-08
KR101267217B1 (ko) 2013-05-31
NZ574717A (en) 2011-11-25
KR20090023685A (ko) 2009-03-05
BRPI0714383A2 (pt) 2013-04-30
AU2007272578A1 (en) 2008-01-17
AU2007272578B2 (en) 2012-11-08

Similar Documents

Publication Publication Date Title
CR10552A (es) Metodos para tratar y limitar trastornos fibroticos y queloides
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
CR20170359A (es) Oligómetros antisentido de tau y usos de estos
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
BRPI0712607A8 (pt) métodos de tratamento de acidente vascular cerebral
SG178873A1 (en) Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
EA201690745A1 (ru) Способы лечения и предотвращения болезни "трансплантат против хозяина"
ECSP20082339A (es) Moduladores de la expresión de apol1
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
CR20210103A (es) Composición farmacéutica para usarse en el tratamiento o prevención de una enfermedad relacionada con c5 y método para tratar o prevenir una enfermedad relacionada con c5
CO2018004684A2 (es) Métodos para tratar la epilepsia
BR112014030279A2 (pt) métodos para tratamento de neutropenia usando agonistas retinóide
WO2013039956A3 (en) Compositions and methods for treating mood disorders
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
MX387658B (es) Métodos para tratar y/o prevenir queratosis actínica.
MX394452B (es) Inhibicion de la actividad de olig2.
MX383462B (es) Pridopidina para el tratamiento de las discinesias inducidas por fármacos
ZA201901367B (en) Inhibition of olig2 activity
MX375612B (es) Composiciones tópicas de pterostilbeno para utilizarse en el tratamiento de la pérdida inducida por uv de la función de barrera en la piel.
MX2015012455A (es) Metodo para el tratamiento de la enfermedad de higado graso.
MX343409B (es) Combinaciones farmaceuticas que incluyen conjugados antiinflamatorios y antioxidantes utiles para tratar trastornos metabolicos.